Driving better healthcare through innovation


The EasyScreen™ SARS-CoV-2 Detection Kit has a 100% match by in silico analysis to the new Omicron variant of the SARS-CoV-2 virus and will efficiently detect the new variant.

SydPath responds to COVID-19 testing demands using our EasyscreenTM SARS-CoV-2 Detection Kits

Progress towards FDA clearance of the EasyScreenTM Enteric Protozoan Detection Kit

Genetic Signatures' SARS-CoV-2 assays identify current variants of concern, with typing solutions in development

Genetic Signatures is pleased to announce the appointment of Dr Neil Gunn to our Board of Directors


Our technology is designed to identify and simplify

The technology not only serves to identify methylation patterns in the
DNA, it can also be used to simplify DNA sequences more generally,
particularly in lower organisms.


Transforming Molecular Diagnostics

We focus on the development and commercialisation of our proprietary platform technology, 3base™. Genetic Signatures has released a suite of real-time PCR based products for the routine detection of infectious diseases under the EasyScreen™ brand.

We're driving innovation together

Our Products

Genetic Signatures is transforming molecular diagnostics via
streamlined sample processing methods linked to highly multiplexed
real-time PCR screening assays.

The EasyScreen™ Detection Kits simultaneously detect a larger
number of pathogen targets in a shorter time than conventional

  • Gastrointestinal Infections

  • Respiratory

  • Sexual Health

  • Anti-Microbial Resistance

  • Meningitis

  • Tropical Disease

GSS Product Range

Media Centre

Resource Types
  • All media
  • Videos
  • Webinar
  • Publications
  • Articles
  • News
  • Blog

Why invest with Genetic Signatures? We're at the forefront of Specialist Molecular Diagnostics.

Find investor resources and ASX announcements here.